Axsome Therapeutics, Inc.
AXSM
$210.63
$2.811.35%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 22.38% | 32.33% | 36.22% | 26.19% | 19.98% |
| Total Depreciation and Amortization | 16.75% | 12.57% | 13.90% | 16.24% | 16.50% |
| Total Amortization of Deferred Charges | -72.84% | -70.42% | -50.64% | -22.46% | 0.98% |
| Total Other Non-Cash Items | -15.92% | -12.07% | -10.53% | -15.63% | 1.47% |
| Change in Net Operating Assets | 191.76% | -89.67% | -169.45% | -114.32% | -168.97% |
| Cash from Operations | 40.93% | 40.22% | 27.26% | 23.85% | 27.98% |
| Capital Expenditure | -48.62% | 48.43% | -77.78% | -77.73% | 10.80% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -48.62% | 48.43% | -77.78% | -77.73% | 10.80% |
| Total Debt Issued | 47.37% | -- | -- | -- | -- |
| Total Debt Repaid | -46.26% | -32,830.21% | -33,648.69% | -39,885.00% | -55,357.88% |
| Issuance of Common Stock | -10.37% | 1.38% | 78.36% | 125.31% | 120.93% |
| Repurchase of Common Stock | -125.06% | -81.03% | -79.91% | -78.40% | -73.97% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 9.86% | -63.48% | -70.18% | -100.20% | -48.42% |
| Cash from Financing | -18.13% | -14.85% | 75.42% | 127.84% | 132.95% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 233.17% | 113.74% | 110.70% | 97.68% | 89.59% |